MindMaze secures $105 million in funding, led by Concord Health Partners, to fund growth on the heels of record year and initiates partnership with American Hospital Association


LAUSANNE, SWITZERLAND & LONDON & BALTIMORE–(BUSINESS WIRE)–MindMaze (“the Company”), a global pioneer in the multi-billion dollar digital neurotherapy market, today announced that it has secured a $105 million round of funding to accelerate its commercial growth plans global, energize ongoing R&D and consolidate the clinical development pipeline of its industry-defining digital therapeutic solutions for a wide range of neurological diseases.

The financing round provides immediate access to funds and a financing facility to finance future growth and acquisitions. The financing was led by Concord Health Partners (“Concord”), a US-based healthcare private equity firm focused on investing in and supporting healthcare companies with technologies and solutions innovations that address quality, cost and access to care, as well as other investors. AlbaCore Capital Group, one of Europe’s leading investors specializing in public and private markets, is building on its existing investment to reflect its continued commitment to society. This round also included participation from London-based Hambro Perks, an investor with deep industry expertise and a global portfolio of disruptive and highly scalable companies, and several family office investment groups. Additionally, as a result of Concord’s investment, MindMaze will initiate a partnership with the American Hospital Association (“AHA”). The AHA is committed to advancing innovative healthcare solutions and serves as a national advocate for its provider member organizations, including nearly 90% of hospitals, health systems, and other healthcare organizations in the states. United States, as well as 300,000 health care organization executives in the field. .

MindMaze ushers in a new era of medicine with new technology-enabled protocolized software and hardware devices to treat severe cognitive and motor deficits. The funding announcement underscores the company’s position as a pioneer in digital neurotherapy after achieving a major reimbursement milestone with Category III codes for asynchronous care. The company is poised to change the paradigm of care for millions of patients and caregivers around the world.

“This funding allows us to accelerate commercial activity and expand our footprint in the United States, as well as gain access to strategic partners as we continue to deploy solutions across the continuum of care at scale. world,” said Tej Tadi, Founder and CEO of MindMaze. “MindMaze has been at the frontier of brain technology since its inception, and we’ve been instrumental in the past decade’s incredible advancements in brain sensing, motion capture, mixed reality platforms, new architectures for brain-inspired computing and machine learning./AI. We are excited that leading strategic growth investors, such as Concord Health Partners and the wider investment community, are seeing the expanded potential of our digital neurotherapy platform as we continue to accelerate humanity’s ability to recover, learn and adapt.

James Olsen, Founder and Managing Partner at Concord, said, “MindMaze has developed the industry-leading technology and approach to digital therapy for neuro-rehabilitation and restoration, delivering clear benefits to patients, providers and payers. We believe this notable advance in treatment and therapy will significantly improve brain health and recovery for a wide range of conditions. We are excited to partner with Tej and the MindMaze team to build on his impressive track record and to support clinical and commercial expansion in the US market.

“The AHA is excited to join initiatives to promote and advance the delivery of digital therapeutic solutions for neurological diseases in accessible settings, and MindMaze will enable our hospitals, healthcare systems and other providers to care to provide innovative new solutions to help treat their patients,” noted Doug Shaw, Senior Vice President, Business Development at the American Hospital Association.

MindMaze is ISO 13485 certified and its product portfolio has received three FDA clearances and four CE marks for multiple clinical indications. Present in more than twenty countries, the company provides seamless digital assessments and treatments across the continuum of care for thousands of patients with neurological conditions. MindMaze is advancing commercialization in the United States by expanding its team and footprint in neurorehabilitation centers, and recently received Category III Current Procedural Terminology (CPT®)1 codes for asynchronous care. With this financing in place, the Company also plans to invest in partnerships with pharmaceutical and medical device companies; develop work with the best academic institutions. With more than 10 ongoing clinical trials in 8 indications, the Company expects to have at least three new digital prescription therapeutic solutions for chronic stroke, Parkinson’s disease and aging/MCI in the next few years.

About MindMaze

MindMaze is a global leader in digital neurotherapy (DTx) solutions whose mission is to accelerate the brain’s ability to recover, learn and adapt. With more than a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is tackling some of the issues the most challenging areas in neurology, including stroke, Alzheimer’s disease and Parkinson’s disease, by creating a universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze’s pioneering FDA-cleared, CE-marked neuro-digital therapies are accelerating patient recovery from many critical neurological conditions. Founded in 2012 by CEO Tej Tadi, PhD, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai. For more information, visit www.mindmaze.com.

About Concord Health Partners

Founded by James Olsen and Joseph Swedish, Concord Health Partners (“Concord”) is a US-based healthcare private equity firm focused on investing in growth-stage companies with innovative technologies that advance healthcare through reduced costs, improved quality, and expanded access to care.

About the American Hospital Association

The American Hospital Association is the national organization representing and serving all types of hospitals, health care networks, and their patients and communities. Nearly 5,000 hospitals, health care systems, networks, other healthcare providers and 43,000 individual members come together to form the AHA. Through our representation and advocacy activities, the AHA ensures that the views and needs of members are heard and considered in the development of national health policies, legislative and regulatory debates and issues. judicial. Our advocacy efforts span the legislative and executive branches and include legislative and regulatory arenas. Founded in 1898, the AHA provides education for health care leaders and is a source of information on health care issues and trends.


Comments are closed.